Jafron Minority Interest vs Income Before Tax Analysis

300529 Stock   25.73  0.54  2.06%   
Jafron Biomedical financial indicator trend analysis is infinitely more than just investigating Jafron Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jafron Biomedical is a good investment. Please check the relationship between Jafron Biomedical Minority Interest and its Income Before Tax accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Minority Interest vs Income Before Tax

Minority Interest vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jafron Biomedical Minority Interest account and Income Before Tax. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Jafron Biomedical's Minority Interest and Income Before Tax is 0.45. Overlapping area represents the amount of variation of Minority Interest that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Jafron Biomedical Co, assuming nothing else is changed. The correlation between historical values of Jafron Biomedical's Minority Interest and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Minority Interest of Jafron Biomedical Co are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Minority Interest i.e., Jafron Biomedical's Minority Interest and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.45
Relationship DirectionPositive 
Relationship StrengthWeak

Minority Interest

Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Jafron Biomedical Co whose combined shares represent less than 50% of the total outstanding shares issued by Jafron Biomedical have a minority interest in Jafron Biomedical.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Jafron Biomedical income statement and is an important metric when analyzing Jafron Biomedical profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.
Most indicators from Jafron Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jafron Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
The current year's Tax Provision is expected to grow to about 119.8 M, whereas Selling General Administrative is forecasted to decline to about 312.9 M.
 2022 2023 2024 2025 (projected)
Operating Income1.0B523.2M601.6M528.6M
Total Revenue2.5B1.9B2.2B1.2B

Jafron Biomedical fundamental ratios Correlations

-0.150.970.980.980.980.961.00.980.610.960.510.960.980.950.990.480.90.970.930.930.860.80.930.730.93
-0.15-0.240.02-0.17-0.02-0.36-0.13-0.050.47-0.380.42-0.36-0.08-0.02-0.110.60.06-0.24-0.06-0.170.250.38-0.41-0.35-0.25
0.97-0.240.910.940.90.990.970.950.430.980.310.980.920.890.940.330.820.930.870.890.780.750.950.790.88
0.980.020.910.950.990.890.970.960.750.890.640.870.970.960.980.630.940.940.940.910.90.850.830.630.9
0.98-0.170.940.950.950.940.970.970.610.950.480.950.950.930.980.440.870.960.910.910.860.750.940.710.92
0.98-0.020.90.990.950.890.970.960.720.890.670.890.990.940.990.610.940.970.940.920.890.830.860.640.92
0.96-0.360.990.890.940.890.960.920.40.990.30.980.910.880.930.270.80.930.860.890.730.680.960.780.89
1.0-0.130.970.970.970.970.960.980.590.960.480.960.970.940.980.460.890.960.930.920.850.80.930.740.91
0.98-0.050.950.960.970.960.920.980.640.930.510.940.950.90.970.520.890.950.930.920.920.840.910.690.91
0.610.470.430.750.610.720.40.590.640.390.840.370.640.680.660.890.730.570.660.570.820.720.330.10.55
0.96-0.380.980.890.950.890.990.960.930.390.30.990.920.870.940.260.80.950.870.890.730.660.980.790.91
0.510.420.310.640.480.670.30.480.510.840.30.290.630.620.590.790.650.550.560.510.630.570.270.090.5
0.96-0.360.980.870.950.890.980.960.940.370.990.290.910.850.930.230.780.950.860.880.740.650.990.80.9
0.98-0.080.920.970.950.990.910.970.950.640.920.630.910.950.990.550.910.970.920.920.850.80.880.690.92
0.95-0.020.890.960.930.940.880.940.90.680.870.620.850.950.960.530.880.90.890.860.810.780.820.640.86
0.99-0.110.940.980.980.990.930.980.970.660.940.590.930.990.960.520.920.980.930.930.860.790.90.690.93
0.480.60.330.630.440.610.270.460.520.890.260.790.230.550.530.520.590.430.490.430.70.70.170.040.37
0.90.060.820.940.870.940.80.890.890.730.80.650.780.910.880.920.590.880.990.960.890.890.750.550.94
0.97-0.240.930.940.960.970.930.960.950.570.950.550.950.970.90.980.430.880.910.930.810.720.940.710.95
0.93-0.060.870.940.910.940.860.930.930.660.870.560.860.920.890.930.490.990.910.980.890.850.830.610.97
0.93-0.170.890.910.910.920.890.920.920.570.890.510.880.920.860.930.430.960.930.980.850.810.860.650.99
0.860.250.780.90.860.890.730.850.920.820.730.630.740.850.810.860.70.890.810.890.850.90.710.460.82
0.80.380.750.850.750.830.680.80.840.720.660.570.650.80.780.790.70.890.720.850.810.90.590.510.75
0.93-0.410.950.830.940.860.960.930.910.330.980.270.990.880.820.90.170.750.940.830.860.710.590.80.89
0.73-0.350.790.630.710.640.780.740.690.10.790.090.80.690.640.690.040.550.710.610.650.460.510.80.67
0.93-0.250.880.90.920.920.890.910.910.550.910.50.90.920.860.930.370.940.950.970.990.820.750.890.67
Click cells to compare fundamentals

Jafron Biomedical Account Relationship Matchups

Jafron Biomedical fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets3.2B4.8B5.4B5.5B6.4B6.7B
Other Current Liab140.8M129.3M5.5M4.9M5.6M5.3M
Total Current Liabilities330.8M386.3M717.2M829.4M953.8M1.0B
Total Stockholder Equity2.8B3.4B3.6B3.1B3.6B3.8B
Other Liab51.1M61.5M52.2M125.8M144.7M151.9M
Retained Earnings1.7B2.3B2.1B2.0B2.3B2.4B
Accounts Payable50.2M60.8M128.5M135.6M156.0M163.8M
Cash1.6B2.3B2.6B2.8B3.2B3.4B
Other Assets107.9M102.4M91.6M225.4M259.2M272.2M
Net Receivables167.4M269.1M221.7M74.9M86.1M115.1M
Inventory120.7M196.5M349.1M385.0M442.7M464.9M
Other Current Assets65.3M75.3M35.6M17.3M19.8M26.1M
Total Liab383.1M1.4B1.8B2.4B2.7B2.9B
Intangible Assets89.9M101.3M100.4M100.4M115.4M121.2M
Common Stock417.3M418.7M799.1M805.5M926.3M972.6M
Property Plant Equipment457.6M639.6M905.5M1.3B1.5B1.5B
Net Tangible Assets1.6B2.1B2.7B3.2B3.7B2.0B
Deferred Long Term Liab3.4M14.8M20.4M36.0M41.3M43.4M
Total Current Assets2.0B3.1B3.3B3.3B3.8B2.1B
Non Current Assets Total1.2B1.8B2.1B2.2B2.6B1.3B
Non Currrent Assets Other58.2M162.8M148.2M107.0M123.0M102.3M
Non Current Liabilities Total52.2M1.0B1.1B1.6B1.8B1.9B
Common Stock Shares Outstanding799.1M805.5M807.7M807.6M928.7M880.0M
Net Invested Capital2.8B4.3B4.8B4.8B5.5B3.4B
Net Working Capital1.7B2.7B2.6B2.5B2.9B2.0B
Capital Stock799.1M805.5M807.7M807.6M928.7M743.6M
Property Plant And Equipment Net905.5M1.3B1.7B1.8B2.0B1.4B
Property Plant And Equipment Gross1.0B1.4B1.9B2.1B2.4B1.6B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jafron Stock

Balance Sheet is a snapshot of the financial position of Jafron Biomedical at a specified time, usually calculated after every quarter, six months, or one year. Jafron Biomedical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jafron Biomedical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jafron currently owns. An asset can also be divided into two categories, current and non-current.